Melatonin — Research Evidence
The summary below was generated by an AI system (Claude) based on the studies listed. It is a synthesis tool, not a clinical opinion. Read individual studies for full context.
Melatonin (N-acetyl-5-methoxytryptamine) is an endogenous hormone produced by the pineal gland in response to darkness, playing a central role in circadian rhythm regulation. Endogenous nocturnal melatonin secretion typically produces serum levels in the range of 100-200 pg/mL, peaking in the middle of the night. Commercial melatonin supplements are commonly sold in doses of 1-10mg — doses that produce serum levels orders of magnitude higher than physiological night-time peaks. This pharmacological reality is central to understanding the evidence base.
The strongest evidence for melatonin supplementation is in circadian rhythm disorders. A systematic review (Brzezinski et al., 2007) found that melatonin taken at the appropriate local bedtime at the destination is effective in reducing jet lag symptoms and accelerating circadian resynchronization, particularly when crossing five or more time zones. Timing of administration is critical: melatonin administered at the wrong circadian phase can worsen circadian misalignment rather than improve it. The evidence for shift work disorder is similarly supported but less extensively reviewed.
For primary sleep disorders in otherwise healthy adults, the evidence is more modest. A meta-analysis (Ferracioli-Oda et al., 2013, 19 studies) found that melatonin reduced sleep onset latency by a mean of approximately 7 minutes and increased total sleep time by approximately 8 minutes compared to placebo. These are statistically significant but clinically modest effects. Importantly, melatonin does not appear to substantially alter sleep architecture (deep sleep, REM proportion) — it functions primarily as a circadian timing signal rather than a sedative.
Dose is a critical and frequently misunderstood variable. Research by Auger et al. (2018) and others supports the principle that 0.5mg can produce circadian phase advances comparable to higher doses, with fewer side effects. The common assumption that higher doses produce greater sleep benefits is not well-supported by evidence. Most experts now recommend starting with the lowest effective dose (0.5mg or below) before escalating.
Long-term safety data is limited. Short-term use (weeks to months) appears well-tolerated in adults. Theoretical concerns exist about chronic high-dose supplementation suppressing endogenous melatonin production via feedback inhibition, though this has not been definitively demonstrated in controlled human trials. Melatonin is not recommended for children without medical supervision. Several drug interactions are relevant, particularly with anticoagulants, immunosuppressants, and hormonal contraceptives.
Key findings
- ✓Strongest evidence is for jet lag: melatonin taken at destination local bedtime accelerates circadian resynchronization, especially when crossing 5+ time zones.
- ✓For primary sleep disorders, melatonin modestly reduces sleep onset latency (~7 min) and increases total sleep time (~8 min) versus placebo — effect sizes are real but small.
- ✓Melatonin is a circadian timing signal, not a sleep architecture enhancer — effects on deep sleep or REM are minimal.
- ✓Low doses (0.5mg) appear as effective as higher doses (5-10mg) for circadian phase shifting, with better tolerability and less next-day sedation.
- ✓Commercial supplement doses (5-10mg) are supraphysiological relative to endogenous nocturnal melatonin levels; physiological supplementation is in the 0.1-0.5mg range.
Evidence gaps
- ?Long-term safety data (beyond several months of continuous use) in adults is lacking.
- ?Whether chronic high-dose use suppresses endogenous melatonin production has not been definitively tested in controlled human trials.
- ?Effects in healthy adults without circadian disruption or sleep disorders are poorly defined.
- ?Optimal dose titration protocols across different use cases (jet lag vs. delayed sleep phase vs. general sleep onset) are not standardized.
- ?Pediatric safety profile requires significantly more study before general use can be supported.
Safety summary
Short-term use in adults appears generally safe. Most common side effects are daytime drowsiness, headache, and dizziness, which are more pronounced at higher doses. Not recommended for children or adolescents without medical supervision. Potential interaction with blood thinners (warfarin), immunosuppressants, hormonal contraceptives, diabetes medications, and CNS depressants (additive sedation). Taking melatonin at the wrong time of day can worsen circadian misalignment. Individuals with autoimmune conditions should consult a healthcare provider, as melatonin has immunomodulatory properties.
Studies (3)
Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders
Melatonin significantly reduced sleep onset latency (mean 7.06 minutes), increased total sleep time (mean 8.25 minutes), and improved overall sleep quality compared to placebo. Effect sizes were modest but statistically significant. Effects were not as large as other sleep medications but the safety profile was favorable.
Melatonin may modestly reduce time to fall asleep and increase total sleep time in adults with primary sleep disorders
Generally well-tolerated in short-term trials; drowsiness and headache most commonly reported
High heterogeneity across included trials; variable doses (0.1mg to 10mg); variable study durations; limited data on long-term use; most studies relied on self-reported outcomes
Melatonin for the Prevention and Treatment of Jet Lag: A Systematic Review
Melatonin taken at the appropriate local bedtime at the destination is effective in reducing jet lag symptoms and accelerating circadian resynchronization, particularly when crossing five or more time zones. Timing of administration was identified as critically important — melatonin taken at the wrong circadian phase may worsen circadian disruption.
Melatonin is effective for reducing jet lag, particularly when crossing five or more time zones; timing relative to local destination time is the key variable
Generally well-tolerated for short-term jet lag use; taking at incorrect time may worsen circadian disruption
Variable doses across studies; jet lag is self-resolving; long-distance eastward travel more difficult than westward; blinding is challenging due to sedative effect
Low-Dose Melatonin Improves Sleep in Adults with Delayed Circadian Phase: A Randomized Controlled Trial
Low doses of melatonin (0.5mg), taken 1-2 hours before desired sleep time, produced meaningful circadian phase advances in adults with delayed circadian phase. Higher doses did not produce proportionally greater circadian shifts and were associated with greater next-day sedation.
Low-dose melatonin (0.5mg) may more effectively advance circadian phase than higher doses; dose-response is not linear
Higher doses (>1mg) associated with next-morning sedation and possible suppression of endogenous melatonin; lower doses better tolerated
Specialized population (delayed circadian phase); findings may not generalize to healthy adults without circadian disorders; relatively short follow-up period